479069-85-7

Upstream product

• 478921-29-8 3-(5-hydroxypentyl)-6-(3-ethyl-4-methylanilino)uracil 
• 14660-52-7 ethyl 5-bromovalerate 
• 478921-27-6 6-amino-2-methoxy-3-[4-(ethoxycarbonyl)butyl]-4-pyrimidone 
• 87986-23-0 3-ethyl-4-methylaniline hydrochloride 
• 870451-83-5 acetic acid 5-[4-(3-ethyl-4-methyl-phenylamino)-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-pentyl ester 
• 478921-24-3 3-(4-Ethoxycarbonylbutyl)-6-(3-ethyl-4-methylanilino)uracil 
• 870451-73-3 acetic acid 5-(4-amino-2-methoxy-6-oxo-6H-pyrimidin-1-yl)-pentyl ester 

Relevant academic research and scientific papers

Synthesis and antibacterial activity of 3-substituted-6-(3-ethyl-4- methylanilino)uracils

Numerous 3-substituted-6-(3-ethyl-4-methylanilino)uracils (EMAU) have been synthesized and screened for their capacity to inhibit the replication-specific bacterial DNA polymerase IIIC (pol IIIC) and the growth of Gram+ bacteria in culture. Direct alkylat

Novel heterocyclic antibacterial compounds

The invention provides heterocyclic organic compounds that inhibit bacterial DNA polymerase IIIC and type II bacterial topoisomerase. The invention further provides compounds that are useful as intermediates in the synthesis of such heterocyclic organic compounds. Syntheses and uses of such heterocyclic organic molecules are also described.